Deutsche Bank AG Sells 1,447 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Deutsche Bank AG cut its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) by 1.0% in the third quarter, HoldingsChannel reports. The fund owned 149,773 shares of the company’s stock after selling 1,447 shares during the period. Deutsche Bank AG’s holdings in Deciphera Pharmaceuticals were worth $5,089,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. BlackRock Inc. raised its stake in shares of Deciphera Pharmaceuticals by 5.6% during the second quarter. BlackRock Inc. now owns 3,681,213 shares of the company’s stock worth $134,768,000 after buying an additional 196,210 shares during the last quarter. CIBC Asset Management Inc bought a new stake in shares of Deciphera Pharmaceuticals during the second quarter worth approximately $20,019,000. Amalgamated Bank raised its stake in shares of Deciphera Pharmaceuticals by 30.9% during the second quarter. Amalgamated Bank now owns 7,170 shares of the company’s stock worth $262,000 after buying an additional 1,691 shares during the last quarter. Virtus ETF Advisers LLC raised its stake in shares of Deciphera Pharmaceuticals by 26.1% during the second quarter. Virtus ETF Advisers LLC now owns 13,846 shares of the company’s stock worth $507,000 after buying an additional 2,867 shares during the last quarter. Finally, Cohanzick Management LLC raised its stake in shares of Deciphera Pharmaceuticals by 25.0% during the second quarter. Cohanzick Management LLC now owns 5,000 shares of the company’s stock worth $183,000 after buying an additional 1,000 shares during the last quarter. 78.98% of the stock is owned by institutional investors.

Deciphera Pharmaceuticals stock opened at $8.87 on Friday. The stock has a market capitalization of $518.73 million, a PE ratio of -1.87 and a beta of 1.52. Deciphera Pharmaceuticals, Inc. has a twelve month low of $7.63 and a twelve month high of $52.43. The company has a 50 day moving average of $9.14 and a 200-day moving average of $24.28.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Tuesday, November 2nd. The company reported ($1.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.29) by ($0.08). The company had revenue of $23.22 million during the quarter, compared to analyst estimates of $23.73 million. Deciphera Pharmaceuticals had a negative net margin of 300.00% and a negative return on equity of 58.56%. During the same quarter last year, the company earned ($1.13) EPS. On average, equities research analysts forecast that Deciphera Pharmaceuticals, Inc. will post -5.14 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on DCPH shares. Truist downgraded shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price target for the stock from $65.00 to $10.00 in a research note on Friday, November 5th. cut shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the company from $72.00 to $12.00 in a report on Monday, November 8th. HC Wainwright decreased their price objective on shares of Deciphera Pharmaceuticals from $25.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, December 1st. Truist Securities cut shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the company from $65.00 to $10.00 in a report on Friday, November 5th. Finally, JMP Securities decreased their price objective on shares of Deciphera Pharmaceuticals from $70.00 to $64.00 and set a “market outperform” rating for the company in a report on Friday, November 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $27.36.

Deciphera Pharmaceuticals Profile

Deciphera Pharmaceuticals, Inc engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors.

Featured Article: What Does Beta Mean In Stock Selection?

Want to see what other hedge funds are holding DCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH).

Institutional Ownership by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.